mk 0663 has been researched along with leflunomide in 2 studies
Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (leflunomide) | Trials (leflunomide) | Recent Studies (post-2010) (leflunomide) |
---|---|---|---|---|---|
549 | 173 | 265 | 1,725 | 173 | 659 |
Protein | Taxonomy | mk 0663 (IC50) | leflunomide (IC50) |
---|---|---|---|
Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | 0.03 | |
Cytochrome P450 1A2 | Homo sapiens (human) | 0.5 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 4.63 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 4.63 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.884 | |
Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | 5.4 | |
Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | 0.009 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Berens, N; Bröcker, EB; Seitz, CS; Trautmann, A | 1 |
1 review(s) available for mk 0663 and leflunomide
Article | Year |
---|---|
Leg ulceration in rheumatoid arthritis--an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Arthritis, Rheumatoid; Etoricoxib; Female; Gram-Positive Bacterial Infections; Humans; Isoxazoles; Leflunomide; Leg; Leg Ulcer; Male; Methotrexate; Middle Aged; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Pyridines; Retrospective Studies; Risk Factors; Sulfones | 2010 |
1 other study(ies) available for mk 0663 and leflunomide
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |